N-alkyl-azacycloalkyl NMDA/NR2B antagonists

Details for Australian Patent Application No. 2006236625 (hide)

Owner Merck & Co., Inc.

Inventors Layton, Mark E.; Sanderson, Philip E.; Kelly, Michael J. III; Rodzinak, Kevin J.

Agent Spruson & Ferguson

Pub. Number AU-A-2006236625

PCT Pub. Number WO2006/113471

Priority 60/672,639 19.04.05 US

Filing date 14 April 2006

Wipo publication date 26 October 2006

International Classifications

A61K 31/55 (1970.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

Event Publications

11 October 2007 PCT application entered the National Phase

  PCT publication WO2006/113471 Priority application(s): WO2006/113471

25 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006236629-Methods and compositions to modulate adhesion and stress tolerance in bacteria

2006236622-Compositions of novel opioid compounds and method of use thereof